ABVC (ABVC BioPharma Inc.) Net Profit

Corporate emblem and logo of abvcpharma.com (ABVC)

The net income of ABVC BioPharma (ABVC), which stood at -0.01, confirms the commitment of ABVC BioPharma (ABVC) to ESG principles and bioethics in the development of plant-based medicines. However, the lack of regular revenue streams and stringent FDA oversight create significant financial risks. Meanwhile, the company is strengthening its image as an ethical innovator by synthesizing Eastern medicine with Western quality standards.

ABVC (ABVC BioPharma, Inc.) Company Net Income history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for ABVC BioPharma, Inc. (ABVC)

- price and consensus price forecast:
Stock Quotes ABVC BioPharma, Inc|ABVC - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ABVC BioPharma, Inc|ABVC - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share ABVC BioPharma|ABVC - Company Book Value|Market-to-Book Ratio abvcpharma.com|ABVC - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital ABVC BioPharma|ABVC - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ABVC BioPharma Inc.|ABVC - Company Aggregate Debts|Debts to Book Value ABVC BioPharma, Inc|ABVC - Company Long-Term Debt|Company Short-Term Loans and Borrowings ABVC BioPharma|Quick Ratio abvcpharma.com
- net income and valuation multiples indicators:
ABVC - Net Profit
Fundamental valuation:ABVC ABVC BioPharma, Inc
Flagship merchandise of ABVC BioPharma Inc.

For an investor in ABVC BioPharma (ABVC), this metric serves as a marker for the monetization efficiency of biotechnological developments and operational resilience. By analyzing the profit generated by ABVC BioPharma through GURU.Markets tools, one can assess the dynamics of net income minus all expenses, which, combined with the implementation of robotic process automation for documentation, confirms the business's commitment to cost reduction and fundamental capitalization growth.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|Net Profit Aquestive Therapeutics Inc AQST|scPharma - Net Profit|TECX: Company Net Income|TNXP (Tonix Pharmaceuticals) - Net Income|SXTC (China SXT Pharmaceuticals, Inc.) - Company Net Income|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Net Income BioHarvest Sciences, Inc. (BHST)|Net Income EXOZ (Invizyne Technologies, Inc.)|ORMP (oramed.com) - Final Profit|Net Profit ENTX (Entera Bio)|ipatherapeutics.com - Company Net Income|Cumberland Pharmaceuticals Inc. - Net Profit|Net Financial Result Quantum BioPharma Ltd. QNTM|FibroGen Corp (FGEN) - Company Net Income|Company Net Income Telomir Pharmaceuticals Corp (TELO)|Company Net Income Rani Therapeutics Holdings|Synergy CHC Corporation - Profit After Tax|Net Profit RLYB|LEXX (lexariabioscience.com) - Final Profit|Net Profit PULM (Pulmatrix Corp)|Net Profit Pheton Holdings Limited PTHL|APM - Company Net Income|Final Profit LYRA (lyratherapeutics.com)|Impact BioMedical Inc (IBO) - Company Net Income|Net Income TNF Pharmaceuticals, Inc.|YCBD (cbdMD Inc.) - Net Profit|Net Profit PainReform Corp|Net Profit CYTO|Net Profit lipella.com (LIPO)|Net Profit OPTN (OptiNose)|Pieris Pharmaceuticals Inc - Company Net Income|PROC: Net Income|PTPI: Company Net Income|QLI: Net Profit|Net Income acelyrin.com|Company Net Income TFF Pharmaceuticals, Inc.